Keyphrases
Neoantigen
81%
Natural Killer Cells
80%
Tumor
61%
CD8+ T Cells
46%
Human Immunodeficiency Virus Type 1 (HIV-1)
44%
Infected Cells
33%
Immune Checkpoint Therapy
33%
CD4+ T Cells
30%
Cell Toxicity
30%
T Cells
29%
Checkpoint Blockade Immunotherapy
26%
Lysis
26%
HIV-infected Cells
24%
Primary T Cells
24%
Cancer Therapy
23%
HIV Patients
22%
Tumor Rejection
22%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
21%
NKG2D
21%
Tumor Immunity
21%
Tumor Cells
20%
Immunogenicity
20%
Mutational Load
20%
Tumor-specific mutant Antigens
20%
Intratumor
20%
Radiation Effects
20%
Immunotherapeutics
20%
Circulating Tumor DNA (ctDNA)
20%
Phenotypic Heterogeneity
20%
Immune Checkpoint
20%
High-dimensional Analysis
20%
CDC1
20%
Immune System
18%
MHC Class II
17%
Cancer Immunotherapy
15%
Epitope
15%
Cell-mediated
14%
Programmed Death-ligand 1 (PD-L1)
14%
Cancer Genomics
13%
Synergize
13%
Bioinformatics Methods
13%
Small Cell Lung Cancer
13%
Patient Selection
13%
Inducible Nitric Oxide Synthase
13%
Phase II Study
13%
Downmodulation
12%
Tumor-specific
12%
HIV Infection
12%
Tumor Antigen
12%
HIV-1 Vpu
12%
Immunology and Microbiology
Neoantigen
100%
T Cell
81%
Natural Killer Cell
78%
Human Immunodeficiency Virus 1
57%
Immunity
56%
Human Immunodeficiency Virus
54%
T-Helper Cell
54%
Cytotoxic T-Cell
53%
Immunotherapy
43%
Tumor Immunity
23%
Tumor Rejection
20%
Vpu
20%
B Cell
20%
Myeloid
20%
Mutational Load
20%
NKG2D
18%
Immunogenicity
17%
Tumor Cell
16%
Cancer Immunotherapy
16%
Immune System
14%
CD4
14%
RNA Sequence
14%
Immune Response
13%
Bioinformatics
13%
Dendritic Cell
13%
Human Immunodeficiency Virus Infection
12%
CX3CR1
12%
Major Histocompatibility Complex
12%
Target Cell
12%
Cytolysis
11%
Tumor-Associated Macrophage
11%
Epitope
11%
Progression Free Survival
11%
Tumor Antigen
11%
Degranulation
11%
Vpr
11%
Effector Cell
10%
Protein Binding
10%
Natural Killer Cell Mediated Cytotoxicity
10%
CD155
10%
DNA Damage Response
10%
Blood Plasma
10%
Lenalidomide
10%
Brentuximab Vedotin
10%
Tumor-Related Gene
10%
Sarcoma Cell Line
10%
Cell Antigen
10%
Host Cell
10%
Immune Escape
10%
Programmed Death-Ligand 1
10%
Medicine and Dentistry
Non Small Cell Lung Cancer
40%
Immunotherapy
37%
Neoplasm
35%
Immunity
33%
Cancer
31%
Malignant Neoplasm
31%
Cancer Immunotherapy
25%
Specific Tumor
22%
Cancer Therapy
20%
Circulating Tumor DNA
20%
Mutational Load
20%
T Cell
19%
Cytotoxic T-Cell
16%
Sarcoma Cell Line
15%
Protein P53
15%
Systemic Therapy
13%
Tumor Rejection
13%
Immune Checkpoint Inhibitor
12%
Diseases
12%
Small Cell Lung Cancer
11%
Lung Cancer
11%
Atezolizumab
10%
Immune Response
10%
Overall Survival
10%
Diffuse Large B-Cell Lymphoma
10%
Brentuximab Vedotin
10%
Chemoradiotherapy
10%
Biological Marker
10%
Ramucirumab
10%
Lenalidomide
10%
Tumor Treating Fields
10%
Tumor Infiltrating Lymphocyte
10%
Nintedanib
10%
Hyaline Membrane Disease
10%
CTLA-4
10%
Tumor Antigen
10%
T-Helper Cell
10%
Tumor Cell
9%
Progression Free Survival
9%
Mutant Protein
8%
Platelet Derived Growth Factor Receptor
6%
Adaptive Immunity
6%
Tumor Progression
6%
Immune System
5%
Adverse Event
5%
Clinical Finding
5%
Induced Mutation
5%
In Vitro
5%
Patient Population
5%
T-Cell Response
5%
